1. Home
  2. ADNT vs MLYS Comparison

ADNT vs MLYS Comparison

Compare ADNT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADNT
  • MLYS
  • Stock Information
  • Founded
  • ADNT 2016
  • MLYS 2019
  • Country
  • ADNT Ireland
  • MLYS United States
  • Employees
  • ADNT N/A
  • MLYS N/A
  • Industry
  • ADNT Auto Parts:O.E.M.
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADNT Consumer Discretionary
  • MLYS Health Care
  • Exchange
  • ADNT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • ADNT 1.1B
  • MLYS 1.0B
  • IPO Year
  • ADNT N/A
  • MLYS 2023
  • Fundamental
  • Price
  • ADNT $15.59
  • MLYS $15.58
  • Analyst Decision
  • ADNT Hold
  • MLYS Strong Buy
  • Analyst Count
  • ADNT 10
  • MLYS 3
  • Target Price
  • ADNT $18.22
  • MLYS $33.00
  • AVG Volume (30 Days)
  • ADNT 1.3M
  • MLYS 866.7K
  • Earning Date
  • ADNT 05-07-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • ADNT N/A
  • MLYS N/A
  • EPS Growth
  • ADNT N/A
  • MLYS N/A
  • EPS
  • ADNT N/A
  • MLYS N/A
  • Revenue
  • ADNT $14,384,000,000.00
  • MLYS N/A
  • Revenue This Year
  • ADNT N/A
  • MLYS N/A
  • Revenue Next Year
  • ADNT $0.45
  • MLYS N/A
  • P/E Ratio
  • ADNT N/A
  • MLYS N/A
  • Revenue Growth
  • ADNT N/A
  • MLYS N/A
  • 52 Week Low
  • ADNT $10.04
  • MLYS $8.24
  • 52 Week High
  • ADNT $28.48
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • ADNT 60.72
  • MLYS 54.41
  • Support Level
  • ADNT $14.55
  • MLYS $15.45
  • Resistance Level
  • ADNT $15.99
  • MLYS $16.11
  • Average True Range (ATR)
  • ADNT 0.43
  • MLYS 0.96
  • MACD
  • ADNT 0.01
  • MLYS -0.05
  • Stochastic Oscillator
  • ADNT 61.24
  • MLYS 51.56

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: